But the fact that patients must take these drugs into perpetuity to maintain their effects makes the potential cost base quite large, especially given the large size of the total addressable market
In this work, the effect of the ketogenic diet in patients with drug-refractory epilepsy is analyzed
Now, Lilly has announced that its novel oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron was effective at reducing blood sugar and has a safety profile consistent with injectable GLP-1s in a Phase 3 study
This review study analyzes human GLP-1 trials, including protocols via injection that may be considered low dose or microdosing
Chen HL, Woo XB, Wang HS, Lin YJ, Luo HX, Chen YH, et al